Agenda: Addressing the Threat of Drug Resistant TB: A Realistic Assessment of the Challenges
8:00 – 8:10
Objectives of the Workshop
Gail Cassell, Eli Lilly
Workshop Chair
8:10 – 9:40 Panel I: SETTING THE STAGE
10 minute presentations followed by a 30 minute panel discussion
Moderator: Ken Castro, Centers for Disease Control and Prevention
Paul Nunn, World Health Organization
Global Incidence of MDR-TB
Yanis Ben Amor, Earth Institute
Undereported Threat of MDR-TB in Africa
Gerald Friedland, Yale University
HIV/MDR-XDR-TB: Implications
Megan Murray, Brigham & Women's Hospital
Number of MDRTB & XDRTB Patients Receiving Treatment Today: Successes/Failures/Consequences
Gao Qian, Shanghai Medical College
Transmission of MDR-TB
Neel Gandhi, Albert Einstein College of Medicine of Yeshiva University
Transmission of XDR-TB
9:40 – 10:00 Break
10:00 – 11:30 Panel II: HOW DID WE GET TO WHERE WE ARE TODAY: DIFFERENT PERSPECTIVES
10 minute presentations followed by a 30 minute panel discussion
Moderator: Richard Chaisson, Johns Hopkins University
Ed Nardell, Brigham & Women's Hospital
Lack of Infection Control
John Ridderhof, Centers for Disease Control and Prevention
Laboratory Capacity: A Global Analysis
Anne Goldfeld, Harvard School Public Health
Drug and Health Care Delivery: Cambodian and Ethiopian Perspectives
Wieslaw Jakubowiak, WHO Country Office Russian Federation (by phone)
Fighting Drug Resistance in Russia: Challenges and Achievements
Paul Zintl, Partners in Health
Drug Supply: The Stop TB Partnership Perspective.
Ruth Levine, Center for Global Development
Critical Role of Accurate Demand Forecasting: Lessons Learned from Malaria
11:30 – 12:30 Lunch
12:30 – 1:20 Keynote Address
"The Research Path to Tuberculosis Control: An NIH Perspective"
Anthony Fauci, National Institute of Allergy and Infectious Diseases
1:20 – 3:00 Panel III: ESSENTIAL BUILDING BLOCKS
10 minute presentations followed by a 20 minute panel discussion
Moderator: Leonard Sacks, Food and Drug Administration
Dale Nordenberg and Hamish Fraser, Brigham & Women's Hospital
Knowledge Management (IT): What do we need and what do we have?
David Persing, Cepheid and Charles Daitch, Akonni Biosystems
Point of Care Diagnostics: How close are we?
Ann Ginsberg, TB Alliance
TB Drug Development: Realities of the Pipeline
Ray Woosley, The Critical Path Institute
Critical Path for Parallel Development of TB Point of Care Diagnostic and Drug Development
Jeff Moe, Duke University
What are the odds? Who will pay? What are the incentives?
3:00 – 3:15 Break
3:15 – 4:15 Panel IV: A BLUEPRINT FOR ACTION
Moderator: Peter Cegielski, Centers for Disease Control and Prevention
Salmaan Keshavjee, Partners in Health
The Plan: From Powder to Patient
Discussants:
Michael Kimerling, Bill and Melinda Gates Foundation
Carol Nacy, Sequella, Inc.
Iain Richardson, Eli Lilly
Caroline Ryan, U.S. Department of State
Sarita Shah, Tugela Ferry Care and Research Collaboration
Alex Sloutsky, University of Massachusetts
Martie Van Der Walt, Medical Research Council South Africa
Charles Wells, Otsuka
4:15 – 5:30 Panel V: THE NEED FOR URGENCY
Fifteen minute presentations followed by 45 minutes of discussion
Moderator: Jim Kim, Partners in Health
Mark Harrington, Treatment Action Group
Lessons from HIV
Paul Farmer, Partners in Health
Lessons from MDR-TB
5:30 SYNTHESIS & NEXT STEPS
Gail Cassell, Eli Lilly
Workshop Chair
Back to Meeting